معرفی
Dr. Alison McCaig is an Affiliate researcher at the University of Glasgow's School of Cancer Sciences, based at the Paul O'Gorman Research Centre within Gartnavel General Hospital in Glasgow. Her research focuses on molecular mechanisms underlying chronic lymphocytic leukemia (CLL), with particular emphasis on signaling pathways that regulate cancer cell survival and response to therapeutic interventions.
McCaig's research interests center on understanding the complex signaling networks in chronic lymphocytic leukemia, particularly examining B cell receptor signaling, CXCR4/CXCL12 axis, and various survival pathways including AKT/mTOR, NF-κB, and DAPK. Her work investigates how targeted inhibitors like dasatinib and CR8 can disrupt these pathways to induce apoptosis in CLL cells, while also exploring mechanisms of treatment resistance in the tumor microenvironment.
- Chronic Lymphocytic Leukemia pathogenesis
- Targeted therapy mechanisms
- Signaling pathway crosstalk in cancer
- Microenvironmental influences on treatment response
Analysis of her publication record from 2010-2019 reveals a consistent focus on molecular oncology approaches to understanding and treating hematological malignancies. Her work demonstrates strong collaboration with other researchers at the University of Glasgow, particularly with Alison M. Michie. The research shows progression from fundamental signaling pathway investigations toward more translational studies examining therapeutic interventions and resistance mechanisms.
Based at the Paul O'Gorman Research Centre, McCaig works within a specialized cancer research environment focused on translational oncology. Her laboratory work appears to involve both in vitro cell culture models and potentially patient-derived samples to investigate CLL biology and treatment responses.
